How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,657 results for

Quetiapine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Comparison of Capillary and Venous Plasma Drug Concentrations After Repeated Administration of Risperidone, Paliperidone, Quetiapine, Olanzapine, or Aripiprazole (PubMed)

Comparison of Capillary and Venous Plasma Drug Concentrations After Repeated Administration of Risperidone, Paliperidone, Quetiapine, Olanzapine, or Aripiprazole Quantification of blood levels of antipsychotic drugs may be useful for managing medication therapy. This open-label, parallel-group study was performed to compare finger-stick-based capillary with corresponding venous plasma concentrations for risperidone, paliperidone, quetiapine, olanzapine, and aripiprazole and their major

Full Text available with Trip Pro

2016 Clinical pharmacology in drug development

102. A Comparison Study of Quetiapine and Risperidone’s Effectiveness and Safety on Treating Alcohol-induced Mental Disorder (PubMed)

A Comparison Study of Quetiapine and Risperidone’s Effectiveness and Safety on Treating Alcohol-induced Mental Disorder Compared with Risperidone, Quetiapine's effectiveness and safety on treating alcohol-induced mental disorder is still unclear.To investigate the clinical effectiveness and safety of Quetiapine on treating alcohol-induced mental disorder.One hundred and forty-eight patients with alcohol-induced mental disorder were divided into the experimental group (75 patients (...) ) and the control group (73 patients) by the treatments they received. The patients in the experimental group were treated with Quetiapine by taking it three times per day orally. The mean (sd) maintenance dose was 151.2(27.3) mg/d, and the treatment cycle was 6 weeks. Patients in the control group received Risperidone once per day orally with a mean (sd) maintenance dose being 2.3(0.9) mg/d, and the treatment cycle was 6 weeks as well. The PANSS scale was used to assess patients' before and after treatment

Full Text available with Trip Pro

2016 Shanghai archives of psychiatry

103. Comparison of Capillary and Venous Drug Concentrations After Administration of a Single Dose of Risperidone, Paliperidone, Quetiapine, Olanzapine, or Aripiprazole (PubMed)

Comparison of Capillary and Venous Drug Concentrations After Administration of a Single Dose of Risperidone, Paliperidone, Quetiapine, Olanzapine, or Aripiprazole Risperidone, paliperidone, quetiapine, olanzapine, and aripiprazole are antipsychotic drugs approved for treating various psychiatric disorders, including schizophrenia. The objective of this randomized, parallel-group, open-label study was to compare finger-stick-based capillary with corresponding venous whole-blood and plasma

Full Text available with Trip Pro

2016 Clinical pharmacology in drug development

104. Low-dose quetiapine complements stimulant response in attention deficit hyperactivity disorder and more (PubMed)

Low-dose quetiapine complements stimulant response in attention deficit hyperactivity disorder and more 28008352 2018 11 13 2045-1253 6 6 2016 Dec Therapeutic advances in psychopharmacology Ther Adv Psychopharmacol Low-dose quetiapine complements stimulant response in attention deficit hyperactivity disorder and more. 384-385 10.1177/2045125316672545 Naguy Ahmed A Al-Manara CAP Centre, Kuwait Centre for Mental Health, Jamal Abdul-Nassir Street, Shuwaikh, State of Kuwait. eng Journal Article

Full Text available with Trip Pro

2016 Therapeutic Advances in Psychopharmacology

105. Heavy Alcohol Drinking Associated Akathisia and Management with Quetiapine XR in Alcohol Dependent Patients (PubMed)

Heavy Alcohol Drinking Associated Akathisia and Management with Quetiapine XR in Alcohol Dependent Patients Heavy drinking contributes to involuntary body movements such as akathisia. Quetiapine has been shown to alleviate symptoms of akathisia; however, its efficacy in the alcohol dependent population is not well established. Thus, we aimed to identify efficacy of Quetiapine in treating akathisia in very heavy drinking alcohol dependent patients. 108 male and female heavy alcohol consuming (...) study participants received 13 weeks of Quetiapine XR. Drinking history (Timeline Followback, TLFB), depression (Montgomery-Asberg Depression Rating Scale, MADRS), and movement (Barnes Akathisia Scale, BARS) measures were collected at baseline (0 W), week 6 (6 W), and week 12 (12 W). The role of drinking, symptoms of depression, and efficacy of Quetiapine for treating akathisia were assessed. In patients with no symptoms of depression (low MADRS), Quetiapine treatment decreased symptoms of akathisia

Full Text available with Trip Pro

2016 Journal of addiction

106. Treatment With Quetiapine for Youth With Substance Use Disorders and Severe Mood Dysregulation

Treatment With Quetiapine for Youth With Substance Use Disorders and Severe Mood Dysregulation Treatment With Quetiapine for Youth With Substance Use Disorders and Severe Mood Dysregulation - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one (...) or more studies before adding more. Treatment With Quetiapine for Youth With Substance Use Disorders and Severe Mood Dysregulation The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT02845453 Recruitment Status : Recruiting

2016 Clinical Trials

107. Pharmacokinetics of Quetiapine Across Pregnancy and Postpartum

Pharmacokinetics of Quetiapine Across Pregnancy and Postpartum Pharmacokinetics of Quetiapine Across Pregnancy and Postpartum - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Pharmacokinetics of Quetiapine (...) Across Pregnancy and Postpartum (Quetiapine) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT02978534 Recruitment Status : Recruiting First Posted : December 1, 2016 Last Update Posted : December 1, 2016 See Sponsor

2016 Clinical Trials

108. Lithium Versus Quetiapine in Treatment Resistant Depression

Lithium Versus Quetiapine in Treatment Resistant Depression Lithium Versus Quetiapine in Treatment Resistant Depression - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Lithium Versus Quetiapine in Treatment (...) the clinical and cost effectiveness of lithium versus quetiapine when used as add-on therapies to antidepressant medication for patients with treatment resistant depression. The Lithium versus Quetiapine in Depression (LQD) study will assess patients over 12 months to establish which (if any) treatment is more likely to improve TRD over a long duration of time. Professor Anthony Cleare is the Chief Investigator and recruitment began in November 2016. Condition or disease Intervention/treatment Phase

2016 Clinical Trials

109. Levomilnacipran ER vs. Adjunctive Quetiapine for Adults With Inadequate Relief With SSRIs in MDD

Levomilnacipran ER vs. Adjunctive Quetiapine for Adults With Inadequate Relief With SSRIs in MDD Levomilnacipran ER vs. Adjunctive Quetiapine for Adults With Inadequate Relief With SSRIs in MDD - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one (...) or more studies before adding more. Levomilnacipran ER vs. Adjunctive Quetiapine for Adults With Inadequate Relief With SSRIs in MDD The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02720198 Recruitment Status : Completed First Posted : March 25, 2016 Last Update Posted : June 19, 2018 Sponsor: Duke

2016 Clinical Trials

110. A Randomized, Placebo-Controlled Pilot Study of Quetiapine-XR Monotherapy or Adjunctive Therapy to Antidepressant in Acute Major Depressive Disorder with Current Generalized Anxiety Disorder. (PubMed)

A Randomized, Placebo-Controlled Pilot Study of Quetiapine-XR Monotherapy or Adjunctive Therapy to Antidepressant in Acute Major Depressive Disorder with Current Generalized Anxiety Disorder. To pilot efficacy and safety data of quetiapine-XR monotherapy or adjunctive therapy to antidepressant(s) in the acute treatment of MDD with current generalized anxiety disorder (GAD).The Mini International Neuropsychiatric Interview was used to ascertain the diagnosis of DSM-IV Axis I disorders. Eligible (...) patients were randomly assigned to quetiapine-XR or placebo for up to 8 weeks. Changes from baseline to endpoint in Hamilton Depression Rating Scale-17 items (HAMD-17), Hamilton Anxiety Rating Scale (HAM-A), Clinical Global Impression-Severity (CGI-S), Quick Inventory of Depression Symptomatology-16 items Self-Report (QIDS-16-SR) total scores, and other outcome measures were analyzed with the last observation carried forward strategy and/or mixed-effects modeling for repeated measures.Of the 34

Full Text available with Trip Pro

2016 Psychopharmacology Bulletin

111. Relative risks of cardiovascular disease in people prescribed olanzapine, risperidone and quetiapine. (PubMed)

Relative risks of cardiovascular disease in people prescribed olanzapine, risperidone and quetiapine. Antipsychotics may confer long term benefits and risks, including cardiovascular disease (CVD) risk. Several studies using routine clinical data have reported associations between antipsychotics and CVD but potential confounding factors and unclear classification of drug exposure limits their interpretation.We used data from The Health Improvement Network, a large UK primary care database (...) to determine relative risks of (CVD) comparing similar groups of people only prescribed olanzapine versus either risperidone or quetiapine. We included participants over 18 between 1995 and 2011. To assess confounding factors we created propensity scores for being prescribed each antipsychotic. We used propensity score matching and Poisson regression to calculate the CVD incidence rate ratios for olanzapine versus the other two drugs.We identified 18,319 people who received a single antipsychotic during

Full Text available with Trip Pro

2016 Schizophrenia Research

112. Comparative effectiveness of quetiapine and haloperidol in delirium: A single blind randomized controlled study. (PubMed)

Comparative effectiveness of quetiapine and haloperidol in delirium: A single blind randomized controlled study. To evaluate the effectiveness of quetiapine and haloperidol in patients of delirium referred to psychiatry consultation liaison services.The study followed a single blind randomised controlled trial design. Thirty-two patients in the haloperidol group and 31 patients in the quetiapine group were assessed at the baseline and 6 consecutive days. Flexible dosing regimen (haloperidol (...) : 0.25-1.25 mg; quetiapine 12.5-75 mg/d) was used. Delirium Rating Scale-Revised-98 (DRS-R-98) and mini mental status examination (MMSE) were the primary and secondary efficacy measures respectively.Baseline DRS-R-98 severity score and MMSE scores did not differ between the 2 study groups. From baseline to day 6, there was significant reduction in the total DRS-R-98 scores, DRS-R-98 cognitive domain scores, DRS-R-98 non-cognitive domain scores and significant increase in the MMSE scores in both

Full Text available with Trip Pro

2016 World journal of psychiatry

113. Steady-state bioequivalence 2-way crossover study of two quetiapine prolonged-release 400 mg tablet formulations in normal male and female healthy subjects under fasting conditions
. (PubMed)

Steady-state bioequivalence 2-way crossover study of two quetiapine prolonged-release 400 mg tablet formulations in normal male and female healthy subjects under fasting conditions
. The purpose of this study was to assess bioequivalence between a generic and a brand quetiapine 400 mg prolonged-release (PR) formulation (Pharmathen S.A.; AstraZeneca Seroquel Prolong®<) in healthy volunteers under steady-state conditions.Randomized, open-label, steady-state, 2-way crossover design in 48 subjects (...) under fasting conditions. As a quetiapine dose of 400 mg was suspected to be high when administered to healthy subjects, we proceeded with an innovative design where subjects were titrated up using 150 mg, 200 mg, and 300 mg daily doses; first treatment (days 4 - 9) and second treatment (days 10 - 15), and then a tapering down phase (days 16 - 17). Blood samples were collected in EDTA K2< tubes prior to each dosing and over a 24-hour sampling schedule on days 9 and 15. Quetiapine was measured

2016 International journal of clinical pharmacology and therapeutics

114. Activating and Tranquilizing Effects of First-Time Treatment with Aripiprazole, Olanzapine, Quetiapine, and Risperidone in Youth. (PubMed)

Activating and Tranquilizing Effects of First-Time Treatment with Aripiprazole, Olanzapine, Quetiapine, and Risperidone in Youth. To assess activating and tranquilizing effects of second-generation antipsychotics (SGAs) in youth.As part of the naturalistic inception cohort study, "Second-generation Antipsychotic Treatment Indication, Effectiveness and Tolerability in Youth (SATIETY)," subjective ratings of activating and tranquilizing symptoms were obtained monthly for 3 months from (...) antipsychotic-naïve youth initiating SGAs using the Treatment Emergent Symptoms Scale (TESS). Discontinuation rates, and TESS-reported symptom rates, and severity were related to clinical and treatment parameters. Two compound measures of TESS were defined: presence of any daytime activating (ACTIVATION+) and sedating symptoms (SEDATION+).In 327 antipsychotic-naïve youth originally initiating the four studied SGAs, discontinuation due to sedation was marginally highest with quetiapine (13.0%) followed

Full Text available with Trip Pro

2016 Journal of Child and Adolescent Psychopharmacology

115. Quetiapine use in adults in the community: a population-based study in Alberta, Canada. (PubMed)

Quetiapine use in adults in the community: a population-based study in Alberta, Canada. The objective of this study was to evaluate trends in prescribing of the second-generation antipsychotic medication quetiapine to adults in the province of Alberta from 2008 to 2013 through examination of dispensed prescriptions, and diagnoses associated with users of quetiapine in 2013.We analysed administrative data from Alberta Health; the Alberta Pharmaceutical Information Network (PIN) Dispenses health (...) data set, the Practitioner Payments (Fee-For-Service claims) health data set and the Population Registry health data set. These data sets allowed us to identify discrete quetiapine recipients for each calendar year from 2008 to 2013. To evaluate diagnoses associated with users of quetiapine, we evaluated diagnostic codes used by physicians in billings claims in 2013.Quetiapine use increased over the 6-year time period studied. In 2008, there were 16,087 unique quetiapine recipients in Alberta (7.2

Full Text available with Trip Pro

2016 BMJ open

116. Efficacy and safety of quetiapine extended release monotherapy in bipolar depression: a multi-center, randomized, double-blind, placebo-controlled trial. (PubMed)

Efficacy and safety of quetiapine extended release monotherapy in bipolar depression: a multi-center, randomized, double-blind, placebo-controlled trial. Quetiapine extended release (XR) has been used to treat various psychiatric disorders, including depressive episodes associated with bipolar I and II disorders. Quetiapine XR is the first approved drug in China for the treatment of bipolar disorder.The study evaluated the efficacy and safety of short-term quetiapine XR monotherapy (...) received quetiapine XR (300 mg/day) and 140 received placebo for 8 weeks. The mean change in the MADRS total score was significantly greater in the quetiapine XR group than in the placebo group (-19.00 ± 7.88 vs. -16.20 ± 9.32; p = 0.004). Adverse events occurred in 96 patients (65.3 %) in the quetiapine XR group and 72 (49.0 %) in the placebo group. The incidence of serious adverse events did not differ significantly between the groups (p = 0.247).This study, which is the first to evaluate 300 mg/day

2016 Psychopharmacology

117. Quetiapine's effect on the SCL-90-R domains in patients with borderline personality disorder. (PubMed)

Quetiapine's effect on the SCL-90-R domains in patients with borderline personality disorder. This study aimed to examine the impact of quetiapine on the symptom and distress domains measured by the Symptom Checklist-90-Revised (SCL-90-R) in patients with borderline personality disorder (BPD).Ninety-five participants meeting DSM-IV diagnostic criteria for BPD were randomly assigned to low-dosage (quetiapine, 150 mg/d; n = 33), moderate-dosage (quetiapine, 300 mg/d; n = 33), or placebo (n = 29 (...) ). SCL-90-R was administered weekly over the course of an 8-week double-blind treatment phase. We used a mixed-effects model to analyze subscale scores of the SCL-90-R.Results showed that both dosages of quetiapine were effective in reducing levels of overall psychological distress, interpersonal sensitivity, depression, and hostility compared with those who received placebo.SCL-90-R can be a useful tool that would allow clinicians to collect information in addition to the DSM symptoms to better

2016 Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists

118. Quetiapine-Induced Syndrome of Inappropriate Secretion of Antidiuretic Hormone (PubMed)

Quetiapine-Induced Syndrome of Inappropriate Secretion of Antidiuretic Hormone The syndrome of inappropriate secretion of antidiuretic hormone (SIADH) can be induced by various conditions, including malignant neoplasms, infections, central nervous system disorders, and numerous drugs. We here report a case of a 65-year-old female patient, treated with quetiapine for schizophrenia, who presented with generalized tonic-clonic seizures and was finally diagnosed with quetiapine-induced SIADH (...) . Quetiapine-associated hyponatremia is extremely uncommon and only a few, relevant reports can be found in the literature. This case underlines the fact that patients on antipsychotic medication and more specifically on quetiapine should be closely monitored and routinely tested for electrolyte disorders.

Full Text available with Trip Pro

2016 Case reports in psychiatry

119. Quetiapine

Quetiapine Quetiapine Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Quetiapine Quetiapine Aka: Quetiapine , Seroquel From Related (...) search on the term "Quetiapine." Click on the image (or right click) to open the source website in a new browser window. Related Studies (from Trip Database) Cost: Medications quetiapine (on 5/17/2017 at ) QUETIAPINE ER 150 MG TABLET Generic $10.87 each QUETIAPINE ER 200 MG TABLET Generic $11.65 each QUETIAPINE ER 300 MG TABLET Generic $15.35 each QUETIAPINE ER 400 MG TABLET Generic $17.19 each QUETIAPINE ER 50 MG TABLET Generic $6.02 each QUETIAPINE FUMARATE 100 MG TAB Generic $0.10 each QUETIAPINE

2018 FP Notebook

120. Bipolar CHOICE (Clinical Health Outcomes Initiative in Comparative Effectiveness): a pragmatic 6-month trial of lithium versus quetiapine for bipolar disorder. (PubMed)

Bipolar CHOICE (Clinical Health Outcomes Initiative in Comparative Effectiveness): a pragmatic 6-month trial of lithium versus quetiapine for bipolar disorder. Bipolar disorder is among the 10 most disabling medical conditions worldwide. While lithium has been used extensively for bipolar disorder since the 1970s, second-generation antipsychotics (SGAs) have supplanted lithium since 1998. To date, no randomized comparative-effectiveness study has compared lithium and any SGA.Within the duration (...) of the study (September 2010-September 2013), participants with bipolar I or II disorder (DSM-IV-TR) were randomized for 6 months to receive lithium (n = 240) or quetiapine (n = 242). Lithium and quetiapine were combined with other medications for bipolar disorder consistent with typical clinical practice (adjunctive personalized treatment [APT], excluding any SGA for the lithium + APT group and excluding lithium or any other SGA for the quetiapine + APT group). Coprimary outcome measures included Clinical

2016 The Journal of clinical psychiatry

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>